Internal Medicine, Hematology & Oncology · Grand Rapids, MI
NPI
1003101429
Since 2011
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
250 Cherry St SE Ste 2200
Grand Rapids, MI, 49503
Phone (616) 685-5600
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.8M
112,411 services
Medicare patients, 2024
493
Average age 72
Drug cost, 2024
$18.5M
3,476 prescriptions
Company payments, 2025
$2,822
From 41 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Erin M Pettijohn was code J1442 (injection, filgrastim (g-csf), excludes biosimilars, 1 microgram), 9,300 times for 13 patients. In total Erin M Pettijohn billed 112,411 services in 174 codes, and Medicare paid $1.8M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-03-13.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1442 Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | Office | 9,300 | 13 | $0.76 | $7,071 |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 3,150 | 16 | $36.01 | $113K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2,080 | 12 | $31.76 | $66K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,318 | 46 | $0.09 | $118 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,200 | 12 | $16.18 | $19K |
| 36415 Venipuncture Blood Collection | Office | 943 | 225 | $8.63 | $8,139 |
| 85025 Blood Count | Office | 942 | 226 | $7.60 | $7,157 |
| 80053 Clinical Chemistry | Office | 675 | 224 | $10.30 | $6,955 |
| 82784 Immunoassay | Office | 541 | 66 | $9.11 | $4,930 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 470 | 16 | $0.72 | $338 |
| 99214 Office E&M - Established | Office | 428 | 214 | $83.13 | $36K |
| 96401 Chemotherapy Administration | Office | 347 | 28 | $49.22 | $17K |
| 83521 Immunoassay | Office | 306 | 56 | $16.93 | $5,179 |
| 83615 Clinical Chemistry | Office | 297 | 161 | $5.91 | $1,754 |
| 96375 Injection Administration | Office | 271 | 69 | $10.47 | $2,837 |
By year: 2022 $1.7M for 77,859 services; 2023 $2.1M for 126,837 services; 2024 $1.8M for 112,411 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 943 | 225 | $8.63 | $8,139 |
| 85025 Blood Count | 942 | 226 | $7.60 | $7,157 |
| 80053 Clinical Chemistry | 675 | 224 | $10.30 | $6,955 |
| 82784 Immunoassay | 541 | 66 | $9.11 | $4,930 |
| 83521 Immunoassay | 306 | 56 | $16.93 | $5,179 |
| 83615 Clinical Chemistry | 297 | 161 | $5.91 | $1,754 |
| 82728 Clinical Chemistry | 171 | 102 | $13.36 | $2,285 |
| 83540 Clinical Chemistry | 168 | 100 | $6.34 | $1,065 |
| 84466 Clinical Chemistry | 163 | 98 | $12.50 | $2,038 |
| 84165 Clinical Chemistry | 149 | 55 | $10.53 | $1,569 |
Medicare prescription drug claims, 2024
In 2024, the drug Erin M Pettijohn prescribed most often to Medicare patients was Acyclovir, with 703 prescriptions and refills. In total Erin M Pettijohn wrote 3,476 Medicare prescriptions that cost $18.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 703 | 824 | 145 | $8,895 |
| Revlimid Lenalidomide | 274 | 274 | 33 | $4.6M |
| Hydroxyurea Generic | 239 | 405 | 53 | $5,046 |
| Imbruvica Ibrutinib | 183 | 183 | 18 | $2.8M |
| Lenalidomide Generic | 161 | 161 | 20 | $2.2M |
| Venclexta Venetoclax | 114 | 114 | 24 | $1.2M |
| Dexamethasone Generic | 101 | 114 | 30 | $1,276 |
| Pomalyst Pomalidomide | 93 | 93 | 13 | $2.1M |
| Allopurinol Generic | 91 | 129 | 39 | $887 |
| Eliquis Apixaban | 80 | 96 | 17 | $52K |
| Ondansetron Odt Ondansetron | 78 | 78 | 50 | $908 |
| Prednisone Generic | 70 | 73 | 35 | $205 |
| Jakafi Ruxolitinib Phosphate | 68 | 68 | Under 11 | $1.2M |
| Imatinib Mesylate Generic | 65 | 67 | Under 11 | $116K |
| Prochlorperazine Maleate Generic | 64 | 64 | 43 | $708 |
Brand drugs: 1,151 claims; generic drugs: 2,325 claims; opioid claims: 56.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Erin M Pettijohn $2,822 ($2,822 in general payments such as food, travel and fees) from 41 companies. The largest payer was Novartis Pharmaceuticals Corporation with $288.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 21 | $288 |
| GlaxoSmithKline, LLC. GSK | 18 | $232 |
| Merck Sharp & Dohme LLC MRK | 7 | $208 |
| Abbvie Inc. ABBV | 8 | $165 |
| Janssen Biotech, Inc. JNJ | 8 | $163 |
| Incyte Corporation INCY | 8 | $152 |
| Genzyme Corporation SNY | 7 | $142 |
| Regeneron Healthcare Solutions, Inc. REGN | 4 | $119 |
| Genentech USA, Inc. ROG.SW | 5 | $116 |
| Pfizer Inc. PFE | 7 | $115 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.